Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;80(1):102-10.
doi: 10.1097/TA.0000000000000865.

Pharmacological targeting of chemokine (C-X-C motif) receptor 4 in porcine polytrauma and hemorrhage models

Harold H Bach 4th  1 , Yee M Wong, Heather M LaPorte, Richard L Gamelli, Matthias Majetschak
Affiliations

Pharmacological targeting of chemokine (C-X-C motif) receptor 4 in porcine polytrauma and hemorrhage models

Harold H Bach 4th et al. J Trauma Acute Care Surg. 2016 Jan.

Abstract

Background: Recent evidence suggests that chemokine receptor CXCR4 regulates vascular α1-adrenergic receptor function and that the noncognate CXCR4 agonist ubiquitin has therapeutic potential after trauma/hemorrhage. Pharmacologic properties of ubiquitin in large animal trauma models, however, are poorly characterized. Thus, the aims of the present study were to determine the effects of CXCR4 modulation on resuscitation requirements after polytrauma, to assess whether ubiquitin influences survival times after lethal polytrauma-hemorrhage, and to characterize its dose-effect profile in porcine models.

Methods: Anesthetized pigs underwent polytrauma (PT, femur fractures/lung contusion) alone (Series 1) or PT/hemorrhage (PT/H) to a mean arterial blood pressure of 30 mmHg with subsequent fluid resuscitation (Series 2 and 3) or 40% blood volume hemorrhage within 15 minutes followed by 2.5% blood volume hemorrhage every 15 minutes without fluid resuscitation (Series 4). In Series 1, ubiquitin (175 and 350 nmol/kg), AMD3100 (CXCR4 antagonist, 350 nmol/kg), or vehicle treatment 60 minutes after PT was performed. In Series 2, ubiquitin (175, 875, and 1,750 nmol/kg) or vehicle treatment 60 minutes after PT/H was performed. In Series 3, ubiquitin (175 and 875 nmol/kg) or vehicle treatment at 60 and 180 minutes after PT/H was performed. In Series 4, ubiquitin (875 nmol/kg) or vehicle treatment 30 minutes after hemorrhage was performed.

Results: In Series 1, resuscitation fluid requirements were significantly reduced by 40% with 350-nmol/kg ubiquitin and increased by 25% with AMD3100. In Series 2, median survival time was 190 minutes with vehicle, 260 minutes with 175-nmol/kg ubiquitin, and longer than 420 minutes with 875-nmol/kg and 1,750-nmol/kg ubiquitin (p < 0.05 vs. vehicle). In Series 3, median survival time was 288 minutes with vehicle and 336 minutes and longer than 420 minutes (p < 0.05 vs. vehicle) with 175-nmol/kg and 875-nmol/kg ubiquitin, respectively. In Series 4, median survival time was 147.5 minutes and 150 minutes with vehicle and ubiquitin, respectively (p > 0.05).

Conclusion: These findings further suggest CXCR4 as a drug target after PT/H. Ubiquitin treatment reduces resuscitation fluid requirements and provides survival benefits after PT/H. The pharmacological effects of ubiquitin treatment occur dose dependently.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ubiquitin and CXCL12 plasma levels after polytrauma. The arrows indicate the time points of polytrauma and drug administration. Shock, shock period; EMS: simulated prehospital emergency medical service period; Resuscitation: simulated in-hospital intensive care unit (ICU) resuscitation period. Open circles, vehicle; light gray squares, 175-nmol/kg ubiquitin; dark gray squares, 350-nmol/kg ubiquitin; gray triangles, 350-nmol/kg AMD3100. Data are mean ± SEM, n = 4–7 per group. A, Ubiquitin plasma concentrations (ng/mL). B, CXCL12 plasma concentrations (pg/mL).
Figure 2
Figure 2
Pharmacologic CXCR4 modulation after polytrauma. The arrows indicate the time points of polytrauma and drug administration. Shock, shock period; EMS, simulated prehospital emergency medical service period; Resuscitation, simulated in-hospital ICU resuscitation period. Open circles, vehicle; light gray squares, 175-nmol/kg ubiquitin; dark gray squares, 350-nmol/kg ubiquitin; gray triangles, 350-nmol/kg AMD3100. Data are mean ± SEM, n = 5–8 per group. *p < 0.05 versus vehicle. A, MAP (mm Hg). B, Fluid requirements to maintain MAP at 70 mm Hg (mL/kg). C, Hematocrit values (%). D, White blood cell counts (WBC, ×109 cells/L).
Figure 3
Figure 3
Ubiquitin treatment after lethal polytrauma and hemorrhage—single dosing. The arrows indicate the time points of polytrauma and drug administration. Shock, shock period; EMS, simulated prehospital emergency medical service period; Resuscitation, simulated in-hospital ICU resuscitation period. Open circles, vehicle; light gray squares, 175-nmol/kg ubiquitin; dark gray triangles: 875-nmol/kg ubiquitin; dark gray diamonds, 1,750-nmol/kg ubiquitin. Data are mean ± SEM, n = 6 per group. *p < 0.05 versus vehicle. A, Ubiquitin plasma concentrations (ng/mL). B, Hemorrhage volume in % of blood volume (BV). C, Hematocrit values (%). D, Kaplan-Meier survival plot.
Figure 4
Figure 4
Ubiquitin treatment after lethal polytrauma and hemorrhage—double dosing. The arrows indicate the time points of polytrauma and drug administration. Shock, shock period; EMS, simulated prehospital emergency medical service period; Resuscitation, simulated in-hospital ICU resuscitation period. Open circles, vehicle (n = 12); light gray squares, 175-nmol/kg ubiquitin (n = 4); dark gray triangles, 875-nmol/kg ubiquitin (n = 10). Data are mean ± SEM. *p < 0.05 versus vehicle. A, Hemorrhage volume in percentage of blood volume (BV). B, Hematocrit values (%). (C), Kaplan-Meier survival plot.
Figure 5
Figure 5
Ubiquitin treatment during continuous hemorrhage without fluid resuscitation. The arrows indicate the time points of polytrauma/start of hemorrhage and drug administration. Open symbols, vehicle (n = 8); gray symbols, 875-nmol/kg ubiquitin (n = 5). Data are mean ± SEM. A, Left y-axis, hemorrhage volume in percentage of blood volume (BV), circles. Right y-axis, MAP (mm Hg), squares. B, Kaplan-Meier survival plot.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1–134. - PubMed
    1. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006;60(6 Suppl):S3–S11. - PubMed
    1. Gomez H, Mesquida J, Hermus L, Polanco P, Kim HK, Zenker S, Torres A, Namas R, Vodovotz Y, Clermont G, et al. Physiologic responses to severe hemorrhagic shock and the genesis of cardiovascular collapse: can irreversibility be anticipated? J Surg Res. 2012;178(1):358–369. - PMC - PubMed
    1. Cohn SM, Blackbourne LH, Landry DW, Proctor KG, Walley KR, Wenzel V. San Antonio Vasopressin in Shock Symposium report. Resuscitation. 2010;81(11):1473–1475. - PubMed
    1. Anand T, Skinner R. Arginine vasopressin: the future of pressure-support resuscitation in hemorrhagic shock. J Surg Res. 2012;178(1):321–329. - PubMed

Publication types